AbbVie Inc. (ABBV)
AbbVie (ABBV) Q4 Earnings and Revenues Surpass Estimates
AbbVie (ABBV) came out with quarterly earnings of $2.16 per share, beating the Zacks Consensus Estimate of $2.13 per share. This compares to earnings of $2.79 per share a year ago.
AbbVie's newer immunology drugs are offsetting Humira's decline, sending stock up 4%
AbbVie's earnings topped estimates as it offered an upbeat view of 2025.
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid arthritis drug that now faces stiff competition.
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
As AbbVie Inc. ABBV and Novartis AG NVS prepare to report their fourth-quarter earnings before market open on Friday, investors are eyeing the technical setups of both pharmaceutical giants.
AbbVie Q4 Earnings Loom: Buy or Sell ABBV Stock Ahead of Results?
Investors' focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports Q4 results later this week.
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
When paired with dividend reinvestment, high-yield dividend stocks have demonstrated remarkable outperformance compared to the S&P 500 over holding periods of 20+ years. This outperformance stems from a fundamental truth: A sustainable high dividend yield often serves as a powerful indicator of intrinsic value.
Why AbbVie Stock Popped While the Market Flopped on Monday
Monday was a grim day for a great many stocks, but luckily for its investors, AbbVie (ABBV 3.88%) wasn't one of them. The storied pharmaceutical company saw its share price rise by almost 4%, on the back of a pair of pre-earnings price target bumps from analysts.
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
AbbVie Inc. ABBV will release its full-year and fourth-quarter 2024 financial results on Friday, Jan. 31.
AbbVie A Top Socially Responsible Dividend Stock With 3.9% Yield
AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.9% yield, as well as being recognized by prominent asset managers as being a socially responsible investment, through analysis of social and environmental criteria. Environmental criteria include considerations like the environmental impact of the company's products and services, as well as the company's efficiency in terms of its use of energy and resources.
3 More Cyclical Stocks to Buy for 2025
In last week's Sunday Digest, I (Tom Yeung) wrote how cyclical companies are often incredible investments. Firms like copper miner Freeport–McMoRan Inc. ( FCX ) usually trade in a predetermined range (much like high and low tides at a beach), and so investors simply need to learn that range and the pattern the stock follows, and then buy low and sell high.
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
AbbVie is expected to beat Q4 2024 revenue and EPS estimates, with strong performance from Skyrizi, Rinvoq, and neuroscience products offsetting Humira's decline. Management expects a return to "robust" mid-single-digit revenue growth in 2025, which suggests full-year 2025 guidance will be largely in line with the analyst consensus. AbbVie is not giving up on emraclidine based on trial conduct and drug exposure observations in the failed phase trial in schizophrenia patients in late 2024.
5 Best CEFs This Month For Nearly 10% Yield (January 2025)
For income investors, closed-end funds, or CEFs, remain an attractive investment class that covers various asset classes and promises high distributions and reasonable total returns. CEFs are generally characterized by higher volatility and deeper draw-downs than the broader market. For these reasons, they are not suited for everyone. In this monthly series, we highlight five CEFs with solid track records that pay high distributions and offer “excess” discounts. We try to separate the wheat from the chaff using our filtering process to select just five CEFs every month from around 500 closed-end funds.
